FDA's advisers on opioids booted for ties to industry, AP learns


Having been buffeted by controversy over its approval of addictive opioid drugs, the FDA is calling on a panel of experts to help it sort through the thorny issue. But even before the new panel met, it has been tinged by controversy itself, dismissing four advisers because of perceived ties to drugmakers.

The panel, selected by the National Academies of Sciences, Engineering and Medicine, held its first meeting this week in Washington, DC. But one day prior, the panel let some advisers know their nominations had been withdrawn, the Associated Press reports. A spokesperson for the academy confirmed to the news service that four advisers were eliminated from the panel but wouldn’t say why. At least two of the four had been called out by Sen. Ron Wyden (D-OR), a vocal critic of pharma’s influence over panels that make recommendations.

One of those is Dr. Gregory Terman, a board member for the American Pain Society, which the AP says has received at least $132,000 in contributions over 18 years from drugmakers that sell painkillers, including Purdue Pharma, Pfizer and Teva.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

The other was Mary Lynn McPherson, currently a professor at the University of Maryland School of Pharmacy, who does work in hospice and end-of-life care. She has been the recipient of residencies and grants for which the industry has contributed at least $300,000, the news service said.

Terman told the AP he learned the day before that he would not be included on the panel. “I responded that I’m very proud of my relationship with the American Pain Society,” Terman said. “We’re the only professional society in the world that thinks of pain science as priority No. 1.”

As for McPherson, a university spokesperson said that any implication that her work had been influenced by the industry was “deeply misguided.”

The FDA for several years has been in the midst of the national controversy for having approved new addictive painkillers even as opioid abuse and overdose deaths have reached what have been referred to as epidemic numbers.

New FDA Director Robert Califf earlier this year outlined an 8-point plan for the FDA that he said would "focus on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief." One of his pledges was to turn to outside experts for guidance on how to balance those needs.  

Other federal agencies also are wrestling with the issue. The Centers for Disease Control and Prevention (CDC) this year released voluntary guidelines aimed at primary care physicians, physician assistants and nurse practitioners who write the majority of opioid prescriptions. They recommend that for short-term pain, clinicians first try alternatives such as nonsteroidal anti-inflammatory drugs and if they prescribe opioids, to start with the minimum dose for just three days. The guidelines don't apply for patients getting pain drugs for cancer or who are receiving end-of-life care.

The National Institutes of Health also is looking to outside experts for advice. Sen. Wyden last week asked the NIH director for info on how its experts are vetted, the AP said.

- read the AP story

Related Articles: 
FDA's Califf calls for 'sweeping re-examination' of policies in effort to fight opioid abuse 
CDC guidelines call for drastic cuts in opioid painkiller use


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.